Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Outcome of adolescents and young adults compared to children with Hodgkin lymphoma treated with response-based chemotherapy on pediatric protocols: A Children's Oncology Group report.

Fernández KS, Schwartz CL, Chen L, Constine LS, Chauvenet A, de Alarcón PA.

Pediatr Blood Cancer. 2017 Dec;64(12). doi: 10.1002/pbc.26681. Epub 2017 Jun 14.

2.

Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031.

Friedman DL, Chen L, Wolden S, Buxton A, McCarten K, FitzGerald TJ, Kessel S, De Alarcon PA, Chen AR, Kobrinsky N, Ehrlich P, Hutchison RE, Constine LS, Schwartz CL.

J Clin Oncol. 2014 Nov 10;32(32):3651-8. doi: 10.1200/JCO.2013.52.5410. Epub 2014 Oct 13.

3.

Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group.

Tebbi CK, Mendenhall NP, London WB, Williams JL, Hutchison RE, Fitzgerald TJ, de Alarcón PA, Schwartz C, Chauvenet A.

Pediatr Blood Cancer. 2012 Dec 15;59(7):1259-65. doi: 10.1002/pbc.24279. Epub 2012 Aug 21.

4.

A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425.

Schwartz CL, Constine LS, Villaluna D, London WB, Hutchison RE, Sposto R, Lipshultz SE, Turner CS, deAlarcon PA, Chauvenet A.

Blood. 2009 Sep 3;114(10):2051-9. doi: 10.1182/blood-2008-10-184143. Epub 2009 Jul 7.

5.

Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis.

Henderson TO, Parsons SK, Wroblewski KE, Chen L, Hong F, Smith SM, McNeer JL, Advani RH, Gascoyne RD, Constine LS, Horning S, Bartlett NL, Shah B, Connors JM, Leonard JI, Kahl BS, Kelly KM, Schwartz CL, Li H, Friedberg JW, Friedman DL, Gordon LI, Evens AM.

Cancer. 2018 Jan 1;124(1):136-144. doi: 10.1002/cncr.30979. Epub 2017 Sep 13.

PMID:
28902390
6.

Childhood Hodgkin International Prognostic Score (CHIPS) Predicts event-free survival in Hodgkin Lymphoma: A Report from the Children's Oncology Group.

Schwartz CL, Chen L, McCarten K, Wolden S, Constine LS, Hutchison RE, de Alarcon PA, Keller FG, Kelly KM, Trippet TA, Voss SD, Friedman DL.

Pediatr Blood Cancer. 2017 Apr;64(4). doi: 10.1002/pbc.26278. Epub 2016 Oct 27.

7.

POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with Stages I, IIA, IIIA1 Hodgkin Disease: a report from the Children's Oncology Group.

Kung FH, Schwartz CL, Ferree CR, London WB, Ternberg JL, Behm FG, Wharam MD, Falletta JM, de Alarcon P, Chauvenet AR; Children's Oncology Group.

J Pediatr Hematol Oncol. 2006 Jun;28(6):362-8.

PMID:
16794504
8.

BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group.

Kelly KM, Sposto R, Hutchinson R, Massey V, McCarten K, Perkins S, Lones M, Villaluna D, Weiner M.

Blood. 2011 Mar 3;117(9):2596-603. doi: 10.1182/blood-2010-05-285379. Epub 2010 Nov 15.

9.

Patterns of relapse from a phase 3 Study of response-based therapy for intermediate-risk Hodgkin lymphoma (AHOD0031): a report from the Children's Oncology Group.

Dharmarajan KV, Friedman DL, Schwartz CL, Chen L, FitzGerald TJ, McCarten KM, Kessel SK, Iandoli M, Constine LS, Wolden SL.

Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):60-6. doi: 10.1016/j.ijrobp.2014.10.042. Epub 2014 Dec 24.

10.

Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.

Franklin J, Eichenauer DA, Becker I, Monsef I, Engert A.

Cochrane Database Syst Rev. 2017 Sep 13;9:CD008814. doi: 10.1002/14651858.CD008814.pub2. Review.

PMID:
28901021
11.

Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin's lymphoma: preliminary results from the Children's Cancer Group Study CCG-59704.

Kelly KM, Hutchinson RJ, Sposto R, Weiner MA, Lones MA, Perkins SL, Massey V; Children's Oncology Group.

Ann Oncol. 2002;13 Suppl 1:107-11.

PMID:
12078889
12.

Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook.

Dörffel W, Lüders H, Rühl U, Albrecht M, Marciniak H, Parwaresch R, Pötter R, Schellong G, Schwarze EW, Wickmann L.

Klin Padiatr. 2003 May-Jun;215(3):139-45.

PMID:
12838937
13.

Predictive Factor Analysis of Response-Adapted Radiation Therapy for Chemotherapy-Sensitive Pediatric Hodgkin Lymphoma: Analysis of the Children's Oncology Group AHOD 0031 Trial.

Charpentier AM, Friedman DL, Wolden S, Schwartz C, Gill B, Sykes J, Albert-Green A, Kelly KM, Constine LS, Hodgson DC.

Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):943-950. doi: 10.1016/j.ijrobp.2016.07.015.

14.

Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95.

Dörffel W, Rühl U, Lüders H, Claviez A, Albrecht M, Bökkerink J, Holte H, Karlen J, Mann G, Marciniak H, Niggli F, Schmiegelow K, Schwarze EW, Pötter R, Wickmann L, Schellong G.

J Clin Oncol. 2013 Apr 20;31(12):1562-8. doi: 10.1200/JCO.2012.45.3266. Epub 2013 Mar 18.

PMID:
23509321
15.

Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.

Skoetz N, Will A, Monsef I, Brillant C, Engert A, von Tresckow B.

Cochrane Database Syst Rev. 2017 May 25;5:CD007941. doi: 10.1002/14651858.CD007941.pub3. Review.

PMID:
28541603
16.

ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial.

Fermé C, Thomas J, Brice P, Casasnovas O, Vranovsky A, Bologna S, Lugtenburg PJ, Bouabdallah R, Carde P, Sebban C, Eghbali H, Salles G, van Imhoff GW, Thyss A, Noordijk EM, Reman O, Lybeert MLM, Janvier M, Spina M, Audhuy B, Raemaekers JMM, Delarue R, Anglaret B, de Weerdt O, Marjanovic Z, Tersteeg RJHA, de Jong D, Brière J, Henry-Amar M; European Organisation for Research and Treatment of Cancer Lymphoma Group, and; Groupe d'Étude des Lymphomes de l'Adulte.

Eur J Cancer. 2017 Aug;81:45-55. doi: 10.1016/j.ejca.2017.05.005. Epub 2017 Jun 8.

PMID:
28601705
17.

Combined therapy in children and adolescents with classical Hodgkin's lymphoma: A report from the SFCE on MDH-03 national guidelines.

Seror E, Donadieu J, Pacquement H, Abbou S, Lambilliotte A, Schell M, Curtillet C, Gandemer V, Pasquet M, Aladjidi N, Lutz P, Schmitt C, Deville A, Minckes O, Vanier JP, Armari-Alla C, Thomas C, Gorde-Grosjean S, Millot F, Blouin P, Garnier N, Coze C, Devoldere C, Reguerre Y, Helfre S, Claude L, Clavel J, Oberlin O, Landman-Parker J, Leblanc T.

Pediatr Hematol Oncol. 2016 Oct - Nov;33(7-8):423-437.

PMID:
27960645
18.

Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials.

Sasse S, Bröckelmann PJ, Goergen H, Plütschow A, Müller H, Kreissl S, Buerkle C, Borchmann S, Fuchs M, Borchmann P, Diehl V, Engert A.

J Clin Oncol. 2017 Jun 20;35(18):1999-2007. doi: 10.1200/JCO.2016.70.9410. Epub 2017 Apr 18.

PMID:
28418763
19.

Patterns of Involved-Field Radiation Therapy Protocol Deviations in Pediatric Versus Adolescent and Young Adults With Hodgkin Lymphoma: A Report From the Children's Oncology Group AHOD0031.

Parzuchowski A, Bush R, Pei Q, Friedman DL, FitzGerald TJ, Wolden SL, Dharmarajan KV, Constine LS, Laurie F, Kessel SK, Appel B, Fernandez K, Punnett A, Schwartz CL, Cox J, Terezakis SA.

Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1119-1125. doi: 10.1016/j.ijrobp.2018.01.002. Epub 2018 Jan 6.

PMID:
29722656
20.

Survival improvement of young patients, aged 16-23, with Hodgkin lymphoma (HL) during the last three decades.

Koumarianou AA, Xiros N, Papageorgiou E, Pectasides D, Economopoulos T.

Anticancer Res. 2007 Mar-Apr;27(2):1191-7.

Supplemental Content

Support Center